# Diabetes Islet Preservation Immune Treatment

> **NCT02586831** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Camillo Ricordi and Jay Skyler**

## Conditions studied

- Diabetes Mellitus, Type 1
- Hypoglycemia
- Autoimmune Diseases
- Diabetes Mellitus

## Interventions

- **DRUG:** Anti-Thymocyte Globulin (ATG)
- **DRUG:** Interleukin 2
- **DRUG:** Exenatide
- **DRUG:** Adalimumab
- **OTHER:** ATG Placebo
- **OTHER:** IL-2 Placebo
- **OTHER:** Adalimumab Placebo
- **OTHER:** Exenatide Placebo

## Key facts

- **NCT ID:** NCT02586831
- **Lead sponsor:** Camillo Ricordi and Jay Skyler
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn prior to enrollment due to funding issues
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586831, "Diabetes Islet Preservation Immune Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02586831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*